deltatrials
Completed PHASE2 NCT00129129

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Evaluate Immuno and Safety of GSKBiologicals' HibMenCYTT vs Licensed Hib Conjugate Vaccine, Each Coadministered With Pediarix® and Prevnar®, in Healthy Infants. An Exploratory Control Group Will Receive Licensed Menomune® at 3 to 5 Years

Sponsor: GlaxoSmithKline

Updated 8 times since 2017 Last updated: Jul 26, 2018 Started: Aug 1, 2004 Primary completion: Sep 15, 2005 Completion: Mar 29, 2006

This PHASE2 trial investigates Haemophilus Influenzae Type b and Neisseria Meningitidis and is currently completed. GlaxoSmithKline leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Sep 2018 — Jan 2021 [monthly]

    Completed PHASE2

Show 3 earlier versions
  1. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bardstown, United States, Beaver Falls, United States, Boardman, United States, Bossier City, United States, Boston, United States, Centennial, United States, Des Moines, United States, Erie, United States, Fountain Valley, United States, Greenville, United States and 12 more location s